Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Expert Explains Role for Newly Approved TKI/mTOR Combo in RCC

May 25th 2016

Sumanta Kumar Pal, MD, provides insight on the FDA approval of the TKI lenvatinib in combination with everolimus, an mTOR inhibitor as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

Dr. Pili on Significance of Entinostat/IL-2 Study in RCC

May 25th 2016

Roberto Pili, MD, professor of Medicine and Robert Wallace Miller Professor of Oncology at Indiana University School of Medicine and a researcher at the Indiana University Melvin and Bren Simon Cancer Center, discusses the significance of the preliminary results of a phase I/II study, which examined the combination of the HDAC inhibitor entinostat and high-dose interleukin-2 (IL-2) in patients with previously untreated metastatic renal cell carcinoma (RCC) of clear cell histology.

Frontline Cabozantinib Improves PFS in Renal Cell Carcinoma

May 23rd 2016

Cabozantinib (Cabometyx) significantly improved progression-free survival compared with sunitinib (Sutent) in treatment-naive patients with advanced renal cell carcinoma in the phase II CABOSUN trial.

Next Steps With Obesity-Related Genes in Patients With RCC

May 23rd 2016

Julia R. Mendoza-Perez, PhD, visiting scientist, Epidemiology, The University of Texas MD Anderson Cancer Center, discusses next steps and research regarding obesity-related genes in patients with renal cell carcinoma (RCC).

Dr. Steinberg on the FDA Approval of Atezolizumab in Bladder Cancer

May 19th 2016

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of Surgery, director of Urologic Oncology, University of Chicago Medicine, discusses the FDA approval of atezolizumab (Tecentriq) as a treatment for patients with with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before or after surgery.

FDA Approves Atezolizumab in Bladder Cancer

May 18th 2016

The FDA granted the PD-L1 inhibitor atezolizumab (Tecentriq) an accelerated approval as a treatment for patients with locally advanced or metastatic urothelial carcinoma (mUC) whose disease progressed during or after platinum-based chemotherapy, or within 12 months of receiving platinum-based chemotherapy, either before or after surgery.

Dr. Choueiri on FDA Approval of Lenvatinib Plus Everolimus in RCC

May 13th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of the combination of lenvatinib (Lenvima) and everolimus (Afinitor) as a treatment for patients with advanced renal cell carcinoma (RCC) following prior anti–angiogeneic therapy.

FDA Approves Lenvatinib/Everolimus for Advanced RCC

May 13th 2016

The FDA has approved the combination of lenvatinib and everolimus as a treatment for patients with advanced renal cell carcinoma (RCC) following prior anti–angiogeneic therapy

PD-1 Expression on Monocytes Potential Immunotherapy Biomarker in RCC

May 13th 2016

Mohammed Haseebuddin, MD, discusses results of a study which demonstrated that elevated preoperative classical monocyte PD-1 mean fluorescence intensity level and lower CM was linked to poor survival in patients with clear cell renal cell carcinoma, as well as the challenges with using PD-1 as a biomarker in these patients.

Dreicer Discusses Pivotal Trial, Excitement With Atezolizumab in mUC

May 12th 2016

Robert Dreicer, MD, provides insight on the IMvigor 210 study and how atezolizumab will dramatically change the treatment paradigm for patients with metastatic urothelial carcinoma, who have a severe unmet need.

Krishna Vanaja Donkena on Using Immune Markers to Predict Survival in Bladder Cancer

May 12th 2016

Krishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.

Liquid Imiquimod Formulation May Induce Immune Response in Bladder Cancer

May 11th 2016

TMX-101 (Vesimune), a liquid formulation of the toll-like receptor 7 agonist imiquimod, appeared safe and demonstrated preliminary clinical activity, including the potential to induce an immune response, in patients with non-muscle invasive bladder cancer.

Molecular Testing, New Biomarkers on Horizon for Immunotherapy in RCC

May 11th 2016

Mark Ball, MD, discusses the clinical, pathological, and genomic profiles of exceptional responders to anti–PD-1 therapy in renal cell carcinoma, the future of immunotherapy, and what significance genomic testing may hold.

Dr. Infante on AM0010 in Patients With RCC

May 11th 2016

Jeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.

Dr. Xifeng Wu on Prognostic Factor of Obesity-Related Genes in RCC

May 4th 2016

Xifeng Wu, MD, PhD, chair, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, director, Center for Translational and Public Health Genomics, professor, The University of Texas MD Anderson Cancer Center, discusses the prognostic factor of obesity-related genes in patients with renal cell carcinoma (RCC).

Expert Shares Insight on Promising Entinostat/IL-2 Results in RCC

May 3rd 2016

Robert Pili, MD, discusses the results and significance of an early-phase trial looking at the combination of entinostat and interleuken-2 and how it could shake up the treatment paradigm for renal cell carcinoma.

Dr. Choueiri on FDA Approval of Cabozantinib for RCC

April 26th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of cabozantinib as a second-line treatment of patients with renal cell carcinoma (RCC).

FDA Approves Cabozantinib for Renal Cell Carcinoma

April 25th 2016

The FDA has approved cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received prior antiangiogenic therapy.

Expert Hopes Immunotherapy Combos Will Deliver Durable Remissions in RCC

April 21st 2016

Robert Figlin, MD, discusses some emerging agents and ongoing trials that could transform the treatment landscape of renal cell carcinoma.

Push for Biomarker Development Continues in RCC and Bladder Cancer

April 21st 2016

Sumanta Kumar Pal, MD, discusses the state of biomarker development in the field of genitourinary malignancies.

NEXT PAGE
PREVIOUS PAGE